ATTENTION Insulet Corporation (PODD) Investors: Possible Fraud - Contact Levi & Korsinsky Today Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws.
During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was "above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers." At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall.
Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis -- a serious medical emergency. The Company's February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.
If you suffered a loss on your Insulet Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290417
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders
2026-03-30 12:10 AM EDT
ATTENTION Insulet Corporation (PODD) Investors: Possible Fraud - Contact Levi & Korsinsky Today
2026-03-30 12:08 AM EDT
GOSS ALERT: Ongoing Investigation Into Gossamer Bio, Inc. - Contact Levi & Korsinsky
2026-03-30 12:06 AM EDT
Dec 01, 2025
The year-end sprint is on. For your Investor Relations team, the time between now and the end of Q1 2026 will be packed with financial reporting, proxy statements, and regulatory filings.
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services